David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
Commentary|Videos|February 25, 2026
Characterizing the Importance of Clinical Trials in Gynecologic Oncology
Author(s)Katherine Kurnit, MD, John Moroney, MD
Fact checked by: Kyle Doherty
John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the importance of clinical trials in gynecologic oncology.
Advertisement
John Moroney, MD, and Katherine Kurnit, MD, MPH, emphasize the role of clinical trials in the advancement of the gynecologic oncology treatment paradigm. They note that although standard-of-care therapies are widely available, clinical trials allow patients to access novel therapies that are not yet widely available. They also underscored that clinical trials offer patients hope in the form of new treatments that are potentially more safe and effective than standard-of-care agents.
Advertisement
Related to this article
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer
3
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
4
UCSF Breast Cancer Specialists Share Expertise on Challenging Breast Cancer Type
5